Background/ Purpose Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ ...

Background Mechanisms for SLE-mediated cognitive impairment (SLE-CI) include autoantibodies and inflammatory molecules normally excluded from the brain by an intact blood brain barrier (BBB). However, ...